Dana-Farber Cancer Institute

Wolfram Goessling, MD, PhD

Wolfram Goessling, MD, PhD

Brigham and Women's Hospital
Dana-Farber Cancer Institute
Harvard Medical School

Developmental signaling pathways govern the formation and function of stem cells, thereby holding the key to unlocking the promise of adult tissue regeneration, and to inhibiting cancer development. In our laboratory, we use zebrafish as the primary model to study the liver and explore the regulation of endodermal progenitor cell specification, organ differentiation and growth.

Thomas S. Kupper, MD

Thomas S. Kupper, MD

Brigham and Women's Hospital
Dana-Farber Cancer Institute
Harvard Medical School

Our laboratory is interested in how immune responses in skin are initiated, and how T cell mediated memory responses occur in skin, and in particular a newly described population of antigen experienced T cells known as Resident Memory T Cell (TRM).

Stuart Orkin, MD

Stuart Orkin, MD

Dana-Farber Cancer Institute
Boston Children's Hospital
Howard Hughes Medical Institute

The laboratory utilizes multidisciplinary approaches to understand how mammalian cells choose specific fates and how mutations in important transcriptional regulators lead to developmental defects or malignancy.

John Quackenbush, PhD

John Quackenbush, PhD

Harvard School of Public Health
Dana-Farber Cancer Institute

Our research group focuses on methods spanning the laboratory to the laptop that are designed to use genomic and computational approaches to reveal the underlying biology. In particular, we have been looking at patterns of gene expression in cancer with the goal of elucidating the networks and pathways that are fundamental in the development and progression of the disease.

Jerome Ritz, MD

Jerome Ritz, MD

Dana-Farber Cancer Institute
Brigham and Women's Hospital
Harvard Medical School

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used in the treatment of patients with hematologic malignancies, but continues to be associated with severe toxicities. Both the effectiveness and toxicity of HSCT are mediated by donor T-cells in the stem cell graft. Those T cells that target antigens expressed on recipient leukemia cells play an important role in eradicating residual tumor cells and preventing leukemia relapse after transplant. In contrast, T cells that target antigens expressed by normal tissues in the recipient are the primary mediators of graft versus host disease (GVHD) and thus lead to substantial toxicities. My laboratory focuses on the assessment of donor immune function after HSCT and characterization of the immune mechanisms responsible for graft versus leukemia (GVL) and GVHD.